Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Total Liabilities (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Total Liabilities for 15 consecutive years, with $1.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 33.94% to $1.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.9 million, a 33.94% decrease, with the full-year FY2024 number at $3.6 million, down 37.9% from a year prior.
  • Total Liabilities was $1.9 million for Q3 2025 at NovaBay Pharmaceuticals, down from $2.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $13.8 million in Q4 2021 to a low of $1.9 million in Q3 2025.
  • A 5-year average of $5.2 million and a median of $5.2 million in 2024 define the central range for Total Liabilities.
  • Biggest YoY gain for Total Liabilities was 372.84% in 2021; the steepest drop was 80.52% in 2021.
  • NovaBay Pharmaceuticals' Total Liabilities stood at $13.8 million in 2021, then tumbled by 57.67% to $5.8 million in 2022, then fell by 2.14% to $5.7 million in 2023, then plummeted by 37.9% to $3.6 million in 2024, then tumbled by 47.83% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Total Liabilities are $1.9 million (Q3 2025), $2.7 million (Q2 2025), and $3.7 million (Q1 2025).